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Neurons have extensive processes and communication between those processes and the cell body is crucial to neuronal function and survival.
Thus, neurons are uniquely dependent on microtubule based transport. Growing evidence supports the idea that deficits in axonal transport
contribute to pathogenesis in multiple neurodegenerative diseases. We describe the motor, cytoskeletal, and adaptor proteins involved in axonal
transport and their interactions. Data linking disruption of axonal transport to diseases such as ALS are discussed. Finally, we explore the
pathways that may cause neuronal dysfunction and death.
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leading to the degeneration and death of motor neurons in
patients with Amyotrophic Lateral Sclerosis (ALS) remain
mysterious. Multiple mechanisms have been proposed,
including protein aggregation, excitotoxicity, oxidative stress,
mitochondrial mysfunction, inflammation, and defects in
axonal transport. Here, we will review the cell biology of
intracellular transport, and focus on the data linking axonal
transport defects to motor neuron degeneration. However,
many of these mechanisms are likely to be linked, so that a
defect in one cellular pathway will have a domino effect
leading to multiple stresses on the cell. The interactions
between axonal transport and other cellular pathways will be
explored. Progress on linking transport defects to pathogen-
esis in a range of neurodegenerative diseases will be reviewed
(Table 1). Finally, we will speculate briefly on the mechan-
isms by which transport deficits may lead to the motor neuron
degeneration observed in ALS.
Motor neurons are large, polarized cells. The motor neuron
cell body is the primary site of metabolic function, and must
continuously supply newly synthesized proteins to extensive
dendritic and axonal processes. The cell body is also the
primary site for degradative functions, such as the degradation⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.04.002of misfolded or aggregated proteins. Given that the axons of
motor neurons can extend for great distances from the cell body,
active transport from cell center to cell periphery, and from the
periphery back to the cell body, is required to maintain the
overall metabolic balance of the cell. Further, communication
between the cell periphery and the cell center is required.
Critical signals, such as neurotrophic factors, trigger signal
transduction pathways leading to the initiation of long-distance
communication along the axon; this signaling also requires
active axonal transport.
1. Molecular motors and the cellular cytoskeleton
Axonal transport occurs along the cellular cytoskeleton. The
cytoskeleton provides the neuron with structural support, but
also remains dynamic, allowing the cell to grow or change in
size and shape over time. There are three major components of
the neuronal cytoskeleton—microtubules, actin, and interme-
diate filaments (Table 1).
Microtubules are formed from the polymerization of αβ-
tubulin dimers. In non-neuronal cells, as well as in developing
neurons, this polymerization is very dynamic. Microtubules
will polymerize outward from the centrosome, then undergo a
stochastic transition, resulting in a very rapid depolymeriza-
tion. This dynamic behavior is required for the normal
outgrowth of the axon and growth cone. However, as neurons
mature, their microtubules become less dynamic, primarily
Table 1
Axonal transport in human disease
Disease name Mutant protein Cellular pathology relevant to transport deficits Refs.
Motor mutations CMT type 2A KIF1B beta reduced transport of synaptic vesicle proteins [103]
spastic paraplegia KIF5A altered microtubule/motor interaction [111,112]
CFEOM type1 KIF21A predicted to disrupt anterograde transport of vesicles [115]
distal SBMA p150Glued reduced microtubule/p150Glued interaction [16,118]
p150 aggregation [50]
Cytoskeletal mutations CMT type 2 HSP27 disruption of neurofilament formation [121,122]
p150 mislocalized and aggregated
HRD TBCE disruption of microtubule stability [123,124]
CMT type 2 NF-L disruption of anterograde and retrograde transport [135,136]
Neurodegenerative diseases
involving axonal transport
Huntington's disease huntingtin disruption of anterograde and retrograde transport [150,151]
axonal swellings
SBMA AR disruption of anterograde and retrograde transport [149,151]
Alzheimer's disease APP/PS1 disruption of anterograde transport [154,156]
axonal blockage
ALS SOD1 deficits in anterograde and retrograde transport [130–132]
dynein/SOD1 aggregates
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(MAPs) that stabilize the polymer. The high concentration
of MAPs such as tau in the axon of mature motor neurons
makes these microtubules significantly more stable. These
microtubules are organized in a polar array along the
axon, with microtubule ‘plus’ ends of exposed β-tubulin
directed outward, and the microtubule ‘minus’ end,
terminating in α-tubulin, directed toward the cell center.
In contrast, microtubules are found in mixed polarity in
dendrites [1].
The actin cytoskeleton also provides both dynamics and
stability. Actin monomers assemble into a flexible helical
polymer with two distinct ends, one fast growing and one slower
growing. In the cell, actin filaments are often bundled into
networks. In developing organisms, actin filaments within
filopodia and lamellipodia are capable of explosive growth,
propelling the growth cone forward during neurite extension.
Actin filaments can be stabilized by interacting proteins; these
stabilized filaments are often associated with the cellular cortex
and provide support at the cell periphery.
The third major component of the cellular cytoskeleton is
intermediate filaments, primarily neurofilaments in mature
motor neurons. Neurofilaments assemble from three subunit
polypeptides: NF-L, NF-M, and NF-H. Once assembled, these
filaments lack overall polarity, and do not undergo the dramatic
remodeling characteristic of actin and microtubules. Neurofila-
ments serve primarily to provide structural stabilization to the
cell, and to regulate the radial growth of axons. Somewhat
surprisingly, neurofilament knockout mice display relatively
mild phenotypes (reviewed elsewhere in this volume). Howev-
er, aggregation of neurofilaments is a common marker of
neurodegenerative disease [2].
Active transport in the neuron relies on molecular motors,
specialized enzymes that use the energy of ATP hydrolysis to
generate movement along the cellular cytoskeleton. Long
distance travel within the motor neuron is driven primarily by
microtubule-based motor proteins, while actin filament-based
motors drive shorter distance, dispersive movements. Microtu-
bule motors include members of the kinesin superfamily andcytoplasmic dynein; myosins drive transport of vesicles and
organelles along actin filaments.
2. Kinesin and the kinesin superfamily
Kinesin was the first axonal transport motor to be identified,
based on assays of vesicular motility along microtubules in
extruded axoplasm [3]. This enzyme, now known as kinesin-1
[4], is a unidirectional motor, driving plus end-directed motility
along microtubules in vitro (Fig. 1). Kinesin is a hetero-tetramer
of two heavy chains and two light chains. Each of the heavy
chains includes an N-terminal motor domain that folds to form a
globular head that is necessary and sufficient for motility in
vitro. The central domain of the polypeptide forms a α-helical
coiled coil that mediates dimerization. Kinesin light chains
associate with the C-terminal domain, which may also bind
directly to intracellular cargos. In its inactive, folded state,
motor function is inhibited by interactions of both the light
chains and C-terminal domain of the heavy chain with the motor
domain localized to the N-terminus of the heavy chain. Cargo
binding results in the unfolding of the complex and the
activation of motor function [5,6].
The two heads of kinesin move in a hand-over-hand
mechanism along the microtubule [7]. This movement is highly
processive, meaning that once bound to the microtubule the
motor will move over long distances prior to detaching [8]. This
processivity makes kinesin a very efficient motor for the
transport of cargo over the long distances of the axon.
Based on homology with the kinesin motor domain, an
extensive superfamily of kinesin-like proteins has been
identified, with 45 members identified in humans [9]. Many
of these proteins also exhibit motor activity. Generally, those
with their motor domains localized at the amino-terminal end
of the polypeptide are plus end-directed motors, similar to
kinesin. Superfamily members with their motor domains
localized to the C-terminal end of the polypeptide have been
shown to move in the opposite direction along microtubules—
toward the microtubule minus end [10]. Finally, a subset of the
kinesin superfamily have their motor domains localized
Fig. 1. Motor neurons depend on axonal transport for cell homeostasis as well as communication between the cell body and periphery. The kinesin superfamily of
anterograde motors is responsible for movement of cargo away from the cell body. Cytoplasmic dynein, in concert with its activator dynactin, is responsible for
retrograde motility directed toward the cell body. Both of these motors run along microtubule “tracks” and drive long-range movements. In contrast, myosins
move along actin filaments, and move cargo over shorter distances. Interactions between a motor and its cargo may be direct, or may be mediated through cargo-
specific adaptor proteins. Bidirectional movement of cargoes may be a result of coordination between kinesin and dynein. In the case of neurofilaments,
bidirectional movement and extended pause time may be caused by a tug-of-war between kinesin and dynein.
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have an unexpected microtubule depolymerization activity [11].
3. Kinesin superfamily members show cargo specificity
Kinesin superfamily proteins share a conserved motor
domain, but diverge significantly throughout the rest of the
molecule, particularly in the cargo-interaction domains. Thus,
members of this superfamily may vary considerably in their
specificity for cargo. Analysis of motor–cargo interactions has
revealed two general observations. First, while there is some
functional redundancy among members of the kinesin super-
family, many of the kinesin-like motors show specificity for
cargo attachments. And second, many cargo attachments are not
direct, but instead are mediated by scaffolding or adaptor
proteins. Research to date has revealed several interesting
mechanisms for cargo recognition and motor attachment, as
well as for directional specificity, such as targeting to axons
versus dendrites. Cargos bound via kinesin light chains include
amyloid precursor protein (APP) and AporER2. These interac-
tions are now thought to be mediated by the adaptor/scaffolding
proteins JIP1 and JIP2 [1]. However, some cargos bind to the
kinesin heavy chain rather than kinesin light chains, such as theGluR2 subunit of the AMPA receptor, which binds via the
adaptor/scaffolding protein GRIP1 [12]. Hirokawa and collea-
gues have proposed an interesting hypothesis to explain these
observations: cargos bound via the kinesin light chains are
preferentially sorted to axons, while direct binding to the
kinesin heavy chain results in transport of cargo to dendrites [1].
Additional kinesin superfamily members also participate in
anterograde transport. Synaptic vesicle precursors are trans-
ported down the axon by members of the kinesin-3 family,
including KIF1A and KIF1Bβ. Both KIF1A and KI-
F1Bβ knockout mice exhibit defects in sensory and motor
neurons, including a loss of synaptic vesicles [1].
Fodrin-associated vesicles are transported by KIF3, a
member of the kinesin-2 family [13]. Microinjection of anti-
KIF3 antibodies blocks both axonal transport and neurite
extension, suggesting that KIF3-mediated transport of fodrin
vesicles is required to supply new materials to the growth cone
to allow for further outgrowth.
4. Cytoplasmic dynein and dynactin
Cytoplasmic dynein is the major motor driving retrograde
transport (Fig. 1). Dyneins were first identified as the motors
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approaches led to the identification of an intracellular dynein
enriched in brain [14]. Cytoplasmic dynein is a ubiquitously
expressed protein in higher eukaryotes, with essential roles in
both cell division and intracellular transport. However, motor
neurons are most vulnerable to defects in dynein function
[15,16].
Cytoplasmic dynein is a large and complex molecule. At the
core of the enzyme is a dimer of two heavy chains (DYNC1H1
[17]), each of which folds to form a motor domain composed of
six AAA motifs, followed by a less well-characterized 7th
domain, yielding a donut-shaped head with 7 distinct
subdomains [18]. These heads are the sites of ATP binding
and force production; the microtubule binding site localizes to a
stalk that projects from the head domain [19]. The N-terminal
domain of the dynein heavy chain forms an extended stem,
which dimerizes to form a two-headed molecule. Also
associated with the dimerization domain at the base of the
motor are a number of intermediate, light intermediate, and light
chains. These polypeptides are thought to function primarily in
cargo association and regulation.
While dynein is sufficient to generate force along micro-
tubules, the accessory or activator complex, dynactin, is
required for most dynein functions in vivo. Dynactin is also a
large and complex molecule, composed of 11 different subunits.
The most distinctive aspect of dynactin is the actin-like filament
that forms the base of the complex, composed of the actin-
related protein Arp1 [20]. Projecting from this filament is a
dimer of an extended coiled-coil protein, p150Glued [21]. This
polypeptide binds directly to cytoplasmic dynein [22,23].
p150Glued also binds directly to microtubules; this additional
microtubule-binding site may serve as a tether to increase the
efficiency of dynein-mediated motility [24,25].
In ensemble assays in which multiple motors function
together to move cargo, dynein moves exclusively toward the
minus end of microtubules. However, more sensitive single
motor assays have revealed more complex dynamics. Studies on
dynein bound to small latex beads have shown that the dynein
motor wanders across the surface of the microtubule, and takes
frequent backward steps [26]. Direct studies of the movement of
fluorescently-labeled dynein/dynactin has revealed even more
surprising aspects of themotility, with dyneinmaking processive
runs in both directions along the microtubule [160]. While the
overall bias is toward minus end-directed motility, the ability of
dynein to change directions may allow the motor to avoid
obstacles encountered during active transport along the axon.
5. Intracellular targeting of the cytoplasmic
dynein–dynactin complex
Cytoplasmic dynein drives retrograde axonal transport, but is
also required for many essential cellular functions including
ER-to-Golgi trafficking, endosome and lysosome motility, and
spindle assembly. The coupling of a single motor to a wide
range of functions suggests that dynein activity is likely to be
carefully controlled. While little is known about the regulation
of dynein motor activity, progress on cargo binding interactionshas suggested that dynein may be coupled to cargo through a
variety of mechanisms, including direct binding of cargo to
multiple dynein subunits, as well as more indirect associations
mediated by dynactin.
Direct interactions have been observed between dynein
intermediate chain (DYNC1I1 and 2) and the protein cargos β-
catenin [27], CKII [28], and neurofilaments [29]. The dynein
light chain Tctex1 (DYNLT1) is also key in mediating cargo
interactions. Tctex1 binds to the Trk neurotrophin receptor [30],
as well as to Fyn tyrosine kinase [31], Doc2 [32] and rhodopsin
[33]. Both the intermediate chain and Tctex1 light chain localize
to the base of the dynein complex.
There is also a role for dynactin in mediating cargo
attachments. Dynactin may act as an adaptor for dynein,
linking the motor to membrane bound vesicles and
organelles. The actin-like Arp1 filament at the base of
dynactin binds to vesicle-associated spectrin [34,35]. Disrup-
tion of the dynactin–spectrin interaction leads to the loss of
dynein from vesicles and the inhibition of minus end-directed
motility along microtubules in extruded squid axoplasm [36].
In C. elegans, spectrin mutants exhibit defects in axonal
transport, although these defects are not as severe as those
observed in dynein or dynactin mutants [37]. The dynactin–
spectrin interaction may therefore function in only a subset
of dynein–cargo linkages.
Regulated associations of dynein with cargo may be
mediated by rab proteins. Rabs are an extensive family of
small GTPases that associate with specific membrane compart-
ments in the cell [38]. Activated rab6 recruits dynein to TGN-
derived vesicles via the proteins BICD or BICD2 [39], while
rab7 and RLIP recruit dynein to lysosomes [40]. Thus, rab-
induced recruitment could provide specific and regulatable
interactions between motor and cargo for a broad range of
cellular transport functions. Intriguingly, a similar mechanism
involving the sequential recruitment of a rab (rab27a), an
adaptor (melanophilin), and a motor (myosin V) has been
shown to regulate melanosome motility in melanocytes
(reviewed in [41]).
5.1. Retrograde transport of neurotrophic factors
Perhaps, one of the most critical cargos that dynein transports
in neurons are trophic factors and signaling molecules.
Neuronal differentiation and survival depends on the transport
of tropic factors from target tissues back to the neuronal cell
body. Neurotrophic factors such as NGF, NT-3, NT-4, and
BDNF bind to membrane-associated receptors and, following
internalization, they are actively transported along the axon.
While there is some debate whether axonal transport of the
trophic factor/receptor complex is absolutely required for
survival [42], transport to the cell body is thought to be
necessary to elicit a full cellular response [43].
Cytoplasmic dynein binds directly to the Trk receptor [30],
and activated Trk co-localizes with dynein in neurons [44].
Dynein is required for the transport of activated receptors from
the axon terminal to the cell body. Inhibition of dynein transport
blocks neurotrophin-stimulated survival of cultured neurons
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transport in the maintenance of healthy neurons.
5.2. Injury signaling and dynein
A clear role for dynein-mediated transport has been
observed in injury signaling. Upon axonal injury, signals are
transported from the lesion site back to the cell body. Perlson
et al. [46] have shown that injury leads to the activation of the
MAP kinase Erk, and that the activated Erk is transported by
dynein. The activated Erk is bound to dynein via a complex
that includes a soluble fragment of the intermediate filament
protein vimentin and the nuclear import factor importin β. In
addition to coupling activated Erk to dynein, vimentin may
also shield phosphorylated Erk from cellular phosphatases
during transport [46]. Thus, the complex as a whole acts to
increase the efficiency of signal transduction, an important
consideration given the long distances signals must travel in
the extended axons of neurons.
5.3. Dynein’s role in protein degradation
One key role for dynein in the neuron may be the removal of
misfolded or degraded proteins from the cell periphery, and the
transport of these proteins back to the cell body for degradation.
Cytoplasmic dynein transports vesicles to the lysosome, and
also drives lyosomal motility along microtubules [47]. Dynein
is also involved in the accumulation of misfolded proteins into
aggresomes, which are pericentrosomal accumulations of
misfolded proteins that build up when the degradative
machinery of the cell is overwhelmed. Dynein drives the
assembly of these structures near the microtubule organizing
center (MTOC) of the cell [48]. Aggresome formation may have
a cytoprotective function, leading to the accelerated turnover of
mutant proteins [49]. Interestingly, however, aggresome
formation is not perturbed in cells from patients with the
G59S mutation in dynactin [50]. Finally, dynein has also been
proposed to play a role in the clearance of misfolded proteins by
autophagy [51].
6. Motor coordination in bidirectional transport
Live cell imaging studies have shown that many organelles,
including vesicles, mitochondria, RNA particles, pigment
granules, neurofilaments, and virus particles, move bi-direc-
tionally along cellular microtubules [52]. These organelles will
move toward one end of the microtubule, then switch directions
and move toward the opposite end, sometimes switching
direction multiple times. In some systems, the overall direction
of motility is regulated, but more often movement appears
stochastic, with frequent and apparently random changes in
direction.
While in vitro motility assays demonstrate that kinesins
and cytoplasmic dynein function independently to produce
motility in opposite directions along microtubules, multiple
studies suggest that the activities of these motors are
coordinately regulated in the cell. For example, antibodiesto either kinesin or dynein/dynactin induce a bi-directional
inhibition of vesicular transport along microtubules in
extruded squid axoplasm [53,54]. Interdependence of ante-
rograde and retrograde motors has also been noted genetical-
ly. Martin et al. [55] identified dominant genetic interactions
between kinesin, cytoplasmic dynein, and dynactin in
Drosophila. Mutations in either motor result in an inhibition
of axonal transport and the accumulation of organelles in
axonal swellings that stain for markers of both anterograde
and retrograde motility.
Several models have been proposed to account for these
observations (reviewed in [56]). In an association model,
motors reversibly associate and disassociate from cargo, and the
motor bound at any given time specifies directionality. This
process might be stochastic, dependent only on the affinity
between the motor and its cargo-bound receptor, or the
interactions may be specifically regulated, for example by a
rab protein. In a tug-of-war model, both plus end-directed and
minus-end directed motors may be simultaneously bound to
cargo, and direction of motility is determined by the dominant
motor at any given time. In a coordinated transport model, the
motors are coordinately regulated so that only a single type of
motor is active at any given time. This coordination may be
direct, mediated perhaps by interactions between the motors or
their adaptor proteins, or indirect and mediated through
mechanisms which may simultaneously activate one set of
motors and inactivate another.
Multiple studies suggest that motors do not rapidly
associate and dissociate from cellular cargo; for example,
robust bidirectional motility of dynein-associated structures
was observed in Dictyostelium expressing GFP-dynein [57].
Accumulating evidence from biophysical studies argue against
the tug-of-war model for lipid droplet and peroxisome motility
[56, 58], although it appears a reasonable model to explain the
net slow axonal transport of neurofilaments (reviewed in [59]).
Therefore, studies have focused on examining the possibility
of coordinate regulation of opposing motor activities. This
type of coordination may be accomplished by the association
of a regulatory factor, which modulates the activity of either
motor.
Another possibility for coordinated motility is that the
motors interact directly. This type of mechanism is consistent
with the strong genetic interactions described by Martin et al.
[55]. Several interactions have been noted to date. The mitotic
kinesin Eg5 was shown to bind to dynactin [60]. Deacon et
al. [61] identified an interaction between kinesin-2 and
dynactin. They found that kinesin-2 competes with cytoplas-
mic dynein for binding to the p150Glued subunit of dynactin.
There is also a direct interaction between kinesin-1 and
cytoplasmic dynein [62]. Together, these observations suggest
a model in which multiple, oppositely oriented motors interact
directly, and therefore may influence each other's activity.
7. Neurofilament transport
The slow transport of neurofilaments from the cell body
toward the synapse contrasts with the faster and more
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filament transport has shown that the net slow anterograde
movement of these polymers is due to ‘stop-and-go’ motility,
where relatively rapid movements of neurofilaments in either
the anterograde or retrograde directions are punctuated by
frequent pauses [63, 64].
The observed velocities for the anterograde excursions are
consistent with the involvement of either conventional kinesin,
or of a kinesin superfamily member. Abnormal neurofilament
distribution was observed in mice with a targeted disruption in
the neuronal kinesin heavy chain KIF5A [65], suggesting a
role for this motor in moving neurofilaments outward along
the axon. However, the observed inhibition was partial, and
restricted to sensory neurons, suggesting additional kinesins
may also bind to and move neurofilaments in vivo.
The retrograde movement of neurofilaments depends on the
motor cytoplasmic dynein. Dynein binds directly to neurofila-
ment subunit NF-M [29], and can move neurofilaments along
microtubules in vitro [66]. Depletion of dynein by RNAi leads
to the accumulation of neurofilaments at the neurite tip in
cultured neurons [67]. In vivo, neurofilament aggregates are
observed in distal axons in mice with a targeted disruption in
dynein/dynactin function [68].
The apparent inefficiency of neurofilament transport is
striking. While kinesin and dynein motors can move vesicles
very quickly, these same motors are capable of moving
neurofilaments only slowly. Both direct observations and
modeling studies predict that the neurofilament remains
stationary more than 90% of the time and that neurofilaments
in the axon spend the bulk of their time detached from the
microtubule [69]. In mature neurons, neurofilaments may
outnumber microtubules by anywhere from 7:1 to 16:1 [69],
so that inefficiency of transport may be a function of lack of
proximity to microtubule tracks. Alternatively, neurofilaments
may be specifically anchored along the axon through nonmotile
links to microtubules.
An alternate hypothesis is that the inefficient transport is a
direct result of an uncoordinated tug-of-war between plus end-
directed and minus end-directed microtubule motors. As
reviewed above, bidirectional vesicular transport appears to
involve motor coordination. In contrast, motors may be
uncoordinated during neurofilament transport, resulting in
slower and less efficient movement. This inefficiency may
provide an overall benefit for the neuron. Neurofilaments in
vitro are prone to tangle, and neurofilament aggregations in vivo
are a marker for degeneration. It may be that an uncoordinated
tug-of-war has the net result of keeping neurofilaments under
tension, and thus preventing tangling and aggregation. Consis-
tent with this hypothesis is the observation of neurofilament
aggregations both in cultured neurons [67] and in vivo [68]
upon disruption of dynein function. These aggregations can
then further impede axonal transport.
8. Mitochondrial transport
Mitochondria play an important role in meeting cellular
metabolic demands, maintaining Ca2+ homeostasis, andregulating apoptosis. Mitochondrial dysfunction can contribute
to excitotoxicity and oxidative stress and has been implicated in
several neurodegenerative diseases, including ALS (reviewed in
[70]). Mitochondria are produced in the cell body, transported to
cell periphery, and then are returned to the cell body for
degradation. Several studies indicate that mitochondria are
distributed preferentially to areas with high metabolic demands,
such as growth cones, nodes of Ranvier and synapses [71–73].
Within neuronal populations, neurons with high activity have
greater densities of mitochondria [74,75].
Mitochondria undergo both anterograde and retrograde
movement along microtubule and actin tracks [76], implying
the involvement of kinesin, dynein, and myosin motors. It is
likely that kinesin-1, conventional kinesin, has a role in plus-
end directed mitochondrial transport. Genetic or biochemical
inhibition of KIF5B restricts migration of mitochondria into
neuronal processes [77,78]. These data do not exclude the
possibility that other kinesins may take part in mitochondrial
transport. Indeed, KIF1Bβ, a member of the kinesin-3 family,
has also been shown to interact directly with mitochondria [79].
Dynein is the proposed motor for retrograde transport of
mitochondria. In Drosophila, mutations in dynein heavy chain
result in axonal swellings composed of multiple organelles,
including mitochondria [55], while expression of a mutant form
of the dynactin subunit p150Glued results in the accumulation of
mitochondria within the cell body [50]. In addition, mitochon-
drial transport may bemediated by coordination between kinesin
and dynein; mutations in kinesin disrupt retrograde as well as
anterograde movement of mitochondria in Drosophila [80].
Movement of mitochondria along actin filaments suggests
that myosin motors also participate in mitochondrial transport.
Myosins I, II, V, and VI are involved in transport of organelles
and vesicles and thus are reasonable candidates for mitochon-
drial transport (reviewed in [81]).
Recently, linker proteins that specifically coordinate mito-
chondria with the transport machinery have been identified.
Mutations in milton result in loss of mitochondria from
neuronal processes, while other organelles retain their normal
distribution [82]. Further, milton co-localizes with mitochon-
dria, but not other organelles, and KIF5B, suggesting that it acts
as a mitochondria specific linker between the mitochondria and
anterograde motor [82]. Syntabulin has also been shown to
coordinate interaction between KIF5B and mitochondria and its
inhibition results in abnormal distribution of mitochondria
[83,84]. Linker proteins that associate with dynein have also
been identified. A mutation in APLIP1, a Drosophila homolog
of JIP-1, while disrupting both anterograde and retrograde
vesicular transport, results in specific inhibition of retrograde
mitochondrial transport. Thus, APLIP1 may mediate associa-
tion between dynein and mitochondria [85].
Bidirectional transport of mitochondria is interrupted by
extended pauses. These pauses may help to target mitochondria
to areas with high metabolic demand. It has been proposed that
the pauses may be facilitated by interaction between mitochon-
dria and the cytoskeleton. Mitochondria associate directly with
neurofilament sidearms; this interaction is mediated by
neurofilament phosphorylation as well as mitochondrial
1100 E. Chevalier-Larsen, E.L.F. Holzbaur / Biochimica et Biophysica Acta 1762 (2006) 1094–1108membrane potential [86]. Disruption of the actin cytoskeleton
decreases pausing and increases mitochondrial motility follow-
ing NGF stimulation, suggesting that actin may also serve as a
docking site for mitochondria [87].
9. Transport of RNA particles
The observation of RNA transport and localization within
dendrites provided new insight into the role of local protein
synthesis in modulating postsynaptic assembly and plasticity.
More recently, attention has focused on RNA transport within
axons (see [88, 89] for reviews). The role of this transport is still
being explored, but several studies suggest functions in both
developing and mature neurons. In developing axons, local
mRNA translation modulates growth cone steering and
guidance during axonal elongation [88]. In mature neurons,
local protein expression is involved in axon regeneration. A
clear role for local protein synthesis has been established in
retrograde signaling in response to injury, which involves the
localized synthesis of importin-β and vimentin [46].
Many of the mRNAs localized within vertebrate axons
encode cytoskeletal proteins, including β-actin, tau, and
neurofilament subunits NF-L, NF-M, and NF-H [88]. These
RNAs may be transported in granules, large complexes of
RNAs and proteins. Isolation of purified RNA granules from
mouse brain led to the identification of 42 different proteins,
including the RNA-transport associated proteins staufen and
FMRP [90].
Live cell imaging of RNA granules has revealed bidirec-
tional movement along the cellular cytoskeleton [90,91]. Long-
range movements generally require microtubules, while shorter
range movements may utilize actin filaments. Two types of
granule motility were observed: rapid, processive movements
and more oscillatory movements with very frequent changes in
direction. Kinesin-1 (KIF5) has been identified as a motor for
the plus end-directed transport of RNA granules along dendritic
microtubules [90]. Knockdown studies in Drosophila S2 cells
confirm the role of kinesin-1, and indicate that the interaction
between the motor and the granule does not involve kinesin
light chain [92]. Results from S2 cells also suggest that
cytoplasmic dynein is the major motor driving the minus end-
directed movement of RNA granules along microtubules. As
has been previously observed in studies on vesicular trafficking,
loss of either kinesin or dynein results in a bi-directional block
in transport [92].
Defects in RNA transport may be linked directly to the
pathogenesis of several neuronal diseases. The FMRP protein
identified as a component of RNA granules is the product of the
fragile X mental retardation gene; loss of this protein leads to a
common hereditary form of mental retardation. More directly
relevant to motor neurons is the protein SMN, also a component
of RNA granules transported along neurites [91]. Loss of full-
length SMN results in the autosomal recessive motor neuron
disease Spinal Muscular Atrophy (SMA). Rossoll et al. [93]
have shown that a deficiency in SMN leads to the altered
localization ofβ-actin mRNA in the growth cones of developing
neurons, which in turn leads to reduced neurite outgrowth.10. Axonal transport in model systems
10.1. Drosophila
Drosophila has served as a powerful model system to
investigate the contributions of axonal transport defects to
neuronal cell death. Mutations in kinesin-1 exhibit neuromus-
cular defects, with progressive distal paralysis [94]. Axons from
kinesin heavy chain mutants develop swellings along their
lengths, which are packed with axonal transport cargos
including vesicles, synaptic membrane proteins, and mitochon-
dria [77]. These accumulated organelles form an ‘organelle jam’
that impedes both anterograde and retrograde transport.
Defects in cytoplasmic dynein and dynactin also disrupt
neuronal function in Drosophila. The dominant negative Glued
mutation in the largest subunit of dynactin disrupts both
neuronal morphology and organization [95,96]. As observed in
kinesin mutants, mutations in either dynein or dynactin result in
a bi-directional block in axonal transport. Genetic interactions
suggest that anterograde and retrograde transport function
interdependently [55].
10.2. C. elegans
The nematode C. elegans has proven to be a powerful model
system to investigate cargo specificity in axonal transport.
Conventional kinesin (kinesin-1) is encoded by the C. elegans
gene Unc-116. Mutations in Unc-116 are lethal early in
development due to defects in cell division. However, less
severe alleles show defects in neuromuscular development,
including uncoordinated movement and locomotion [97].
Studies on the kinesin-3 family member Unc-104 have
shown that this motor is specific for the transport of
presynaptic vesicles. Unc-104 mutants are viable, with no
overt disorganization of the nervous system. However, the
worms are paralyzed due to reduced numbers of presynaptic
vesicles at nerve endings [98–100]. The movement of GFP-
UNC-104 in living C. elegans was visualized directly by
Zhou et al. [101], who observed persistent movements at
1 μm/s along both axons and dendrites. The cargo-binding
domain of UNC-104 has been mapped to a pleckstrin
homology (PH) domain in the C-terminal tail, which interacts
with PI(4,5)P2 to target the motor to synaptic vesicles in vivo
[100]. The association of UNC-104 with cargo may also be
regulated by the JNK-signaling scaffold protein UNC-16, a
homolog of mouse JIP3 [102].
Mutations in genes encoding subunits of cytoplasmic dynein
or dynactin also result in the misaccumulation of synaptic
proteins. Dynein is thought to be the major retrograde motor for
axonal transport, but somewhat surprisingly, only a subset of
presynaptic proteins were mislocalized in dynein mutant
worms, including synaptobrevin and synaptotagmin, and the
kinesin motor UNC-104 [37]. Ultrastructural studies revealed
the accumulation of irregularly shaped vesicles at axon tips,
consistent with a defect in vesicular transport. The severity of
the phenotypes induced by dynein and dynactin mutations was
observed to increase with age, leading to a decrease in lifespan.
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Mouse models of axonal transport defects have proven to be
strikingly predictive of human disease. For example, kif1B+/−
mice, which express only a single copy of the gene encoding
KIF1Bβ, develop chronic neuropathy [103]. The observation of
this phenotype led to the identification of a point mutation in the
homologous human gene as a cause of Charcot–Marie–Tooth
Disease Type 2A (described below).
Additional transgenic and knockout models have provided
insight into the specific functions of kinesin superfamily
members. For example, prenatal loss of KIF5A is lethal;
postnatal inactivation of gene expression in neurons leads to the
inhibition of neurofilament transport, reduction in axonal
caliber in sensory neurons, and age-dependent neuronal
degeneration [65]. These studies have revealed some novel
functions for superfamily members, such as the role of the
microtubule depolymerizing kinesin KIF2A in the suppression
of collateral branches during neuronal development [104]. In
contrast, a number of gene targeting studies have suggested
significant functional redundancy among members of the
kinesin superfamily, as knockouts have often revealed no
significant defects in development or neuronal function (KIF1C
[105], KIF3C [106], KIFC2 [107], KIFC3 [108]). Finally,
animal modeling studies have also revealed some surprising
observations; transgenic mice overexpressing KIF17, which
participates in the trafficking of NMDA receptors, exhibit an
enhancement of spatial and working memory [109].
Mouse models with disruptions in dynein/dynactin function
have also been predictive in linking axonal transport defects to
human disease. Loss of dynein in a targeted knockout is lethal
[110], consistent with multiple critical roles for the motor in cell
division and vesicular trafficking. However, mice with a
targeted disruption of dynein/dynactin function in motor
neurons exhibit a phenotype of late onset, slowly progressive
motor neuron disease, marked by the selective loss of large
caliber motor neurons [68]. Similarly, two ENU-induced point
mutations in the DYNC1H1 gene encoding the cytoplasmic
dynein heavy chain, Loa and Cra1, each result in a similar
phenotype of motor neuron-specific cell death [15]. These two
mutations are lethal when homozygous; heterozygous mice
develop late onset and slowly progressive degeneration of
motor neurons. As noted below, these phenotypes are strikingly
similar to the motor neuron disease observed in humans
carrying an autosomal dominant mutation in the DCTN1 gene
encoding a subunit of dynactin [16].
11. Axonal transport defects in human disease
11.1. KIF1B
A mutation in the gene encoding a member of the kinesin-
3 family, KIF1Bβ, has been identified as the cause of disease
in patients with Charcot–Marie–Tooth Disease Type 2A
(CMT2A) [103]. CMT2A patients have an autosomal
dominant neuropathy, leading to weakness and atrophy of
distal muscles. A point mutation alters a highly conservedresidue in the ATP binding site of the motor; in vitro studies
indicate that this mutation is sufficient to significantly inhibit
motor function. KIF1Bβ is a motor for synaptic vesicle
precursors, including synaptotagmin, synaptophysin, and
SV2. Loss of KIF1Bβ is lethal in knockout mice, while
heterozygous kif1B+/− mice are haplo-insufficient, develop-
ing chronic neuropathy, due to the impaired axonal transport
of synaptic vesicle proteins [103].
11.2. SPG10
While the most common causes of pure hereditary spastic
paraplegia are mutations in the spastin gene (discussed
below), three distinct autosomal dominant missense mutations
have been mapped to the SPG10 gene [111–113]. This gene
encodes the heavy chain of kinesin-1 (KIF5A). In two of
these pedigrees, the mutation alters a highly conserved
residue within the motor domain sequence; the third occurs
in the “neck” domain. One mutation is predicted to block
microtubule activation of ATP hydrolysis, one mutation
impairs microtubule-binding affinity, and the third may inhibit
dimerization; these mutations are predicted to severely impact
function. In these cases, affected patients display distal axonal
degeneration, consistent with an inhibition of anterograde
axonal transport [111–113].
11.3. CFEOM1
Mutations in the FEOM1 locus result in congenital fibrosis
of the extraocular muscles type 1. This locus encodes the
kinesin-4 family member KIF21A [114]. The predicted
structure of the KIF21A polypeptide is similar to that of
conventional kinesin, with an N-terminal motor domain, a
central coiled-coil stalk, and a C-terminal tail domain with
seven WD40 repeats that may interact with cargo. The related
family member KIF4 drives the anterograde transport of
vesicles during growth cone guidance and axonal outgrowth
[115]; by analogy, KIF21A is also predicted to participate in
anterograde axonal transport.
KIF21A is expressed throughout mammalian brain, so the
mechanisms leading to the limited phenotype of profound
atrophy of the extraocular muscles remain to be determined. At
least six different disease-causing mutations within KIF21A
have been identified, all of which affect highly conserved
residues [114]. Most of the mutations identified to date disrupt
the coiled-coil domain of the polypeptide, and are predicted to
affect either dimerization or association with an accessory
polypeptide. The most common mutation (R954W) has also
been identified as a de novo mutation in sporadic cases,
suggesting that this region of the gene is a hotspot for genetic
variation [114,116,117].
11.4. DCTN1
A mutation in the DCTN1 gene, encoding the dynactin
subunit p150Glued, results in motor neuron degeneration in an
Alabama kindred [16]. Affected patients develop adult-onset
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weakness and atrophy. Clinical and electrophysiological studies
indicate that the mutation results in the selective loss of motor
neurons [118].
The G59S mutation lowers the affinity of p150Glued for
microtubules, and cell lines from affected patients exhibit
defects consistent with a subtle disruption of dynein/dynactin
function [50]. However, the G59S mutation also disrupts the
folding of p150Glued polypeptide [50], resulting in the formation
of large-scale aggregates in patient motor neurons [118]. Thus,
the point mutation in p150Glued causes both the loss of dynein/
dynactin function and a gain of toxic function, which together
lead to motor neuron cell death.
Sequence analysis of the DCTN1 gene in ALS patients has
revealed additional genetic variability, including heterozygous
missense mutations in patients with both sporadic and familial
ALS [119]. Also, a heterozygous R1101K mutation was
identified in a family with both ALS and frontotemporal
dementia, with an autosomal dominant pattern of inheritance
[120]. Further work will be required to determine whether these
changes represent allelic variants or causative factors for ALS.
12. Mutations affecting the neuronal cytoskeleton
While mutations in motor proteins will directly affect axonal
transport, mutations that affect the integrity of the cytoskeleton
are also likely to perturb transport efficiency. A number of
recently characterized mutations resulting in neuronal degener-
ation may shed further light on the role of the cytoskeleton in
maintaining neuronal homeostasis.
12.1. HSPB1
The HSPB1 gene encodes the small heat shock protein
HSPB1 (HSP27). Mutations in this gene result in distal
hereditary motor neuronopathy and axonal Charcot–Marie–
Tooth Disease [121]. Mutations in HSPB1 disrupt neurofila-
ment assembly [121,122]. Interestingly, expression of mutant
HSPB1 also leads to the mislocalization and aggregation of the
dynactin subunit p150Glued in studies in transfected neurons,
suggesting that the mutation may affect components of the
machinery for axonal transport. Anterograde transport was not
apparently affected, as no alterations in the trafficking of the
vesicle-associated protein synaptotagmin I were observed
[122].
12.2. TBCE mutations
The autosomal recessive progressive motor neuronopathy
(pmn) mouse expresses a point mutation in the gene encoding
tubulin-specific chaperone E (Tbce) [123,124]. While this
mutation is ubiquitously expressed, motor neurons are uniquely
affected. Mutant mice develop progressive motor neuron
disease leading to death within three weeks. The mutation
destabilizes microtubules in motor neurons, leading to axono-
pathy and apoptosis. Neurons cultured from affected mice
exhibit shorter axons with axonal swellings. This destabilizationof neuronal microtubules is likely to affect transport, although
direct measurements have not yet been made,
Surprisingly, a mutation in the homologous human gene,
TBCE, results in a distinct syndrome of congenital hypopara-
thyroidism, mental retardation, facial dysmorphism and growth
failure [125]. However, this mutation also results in an apparent
destabilization of cellular microtubules. The differences in
neuronal susceptibility observed in mouse and human remain to
be explored.
12.3. Spastin mutations
More than 40% of pure hereditary spastic paraplegias are due
to mutations in the spastin gene, resulting in a progressive
length-dependent axonopathy affecting the corticospinal tract.
The spastin gene encodes an AAA family ATPase that severs
microtubules [126,127]. Studies in Drosophila have shown that
loss of spastin results in aberrantly stabilized microtubules
within neurons, as well as defects in synaptic growth and
neurotransmission [128]. The degenerative phenotype observed
in the human disease suggests that microtubule severing and
perhaps remodeling may be important in the maintenance of
elongated axons. Mutations in spastin may also lead to the
disruption of organelle transport [129].
13. Axonal transport defects in ALS
13.1. SOD1
Mutations in the gene encoding superoxide dismutase 1
(SOD1) are the most common cause of familial ALS. While
expression of mutant forms of SOD1 has been shown to have
multiple deleterious consequences for motor neurons (reviewed
elsewhere in this volume), a clear link has been shown between
expression of mutant SOD1 and defects in axonal transport.
Axonal transport defects have been observed in mouse
models expressing mutant forms of SOD1. Defects in slow
anterograde transport, including the slowing of neurofilament
transport, are apparent just prior to disease onset [130,131].
Defects in retrograde transport, from muscle to motor neuron,
have also been observed in mice expressing the SOD1G93A
mutation; inhibition of retrograde transport appears to be one of
the earliest defects apparent in this model [132].
Cytoplasmic dynein co-localizes with aggregates of mutant
SOD1 in motor neurons [132]. While no direct interaction
between SOD1 and dynein has been observed, an indirect
interaction might be mediated by HDAC6. This protein, a
deacetylase, binds to both polyubiquinated misfolded proteins
and to cytoplasmic dynein [133], and therefore may recruit
dynein to aggregates of misfolded SOD1. Presumably, this
interaction would assist the cell in clearing misfolded proteins
through the aggresome pathway.
Somewhat surprisingly, however, defects in cytoplasmic
dynein may ameliorate rather than exacerbate the motor neuron
degeneration induced by expression of mutant SOD1.
SOD1G93A mice were crossed to mice with a point mutation
in cytoplasmic dynein (Loa), and compared to mice carrying
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SOD1G93A/Loa mice survived up to 35 days longer than mice
expressing the SOD1G93A transgene in a wild type dynein
background [134]. The effect was seen at the cellular level as
well. While motor neurons cultured from SOD1G93A or
homozygous Loa mice display defects in retrograde transport,
no transport defects were observed in motor neurons from the
SOD1G93A/Loa cross. The mechanisms involved in the
recovery of transport and the improvement in lifespan are not
yet clear.
13.2. Neurofilaments
Neurofilament aggregates are a common pathological
marker for neurodegenerative diseases such as ALS. The
role of neurofilament mutations as a causative factor for ALS
is reviewed elsewhere in this issue. However, several
mutations in the gene encoding neurofilament light chain
(NF-L) have been shown to cause the inherited peripheral
neuropathy Charcot–Marie–Tooth disease [135,136]. Expres-
sion of these mutant forms of NF-L results in a bi-directional
inhibition of microtubule-based transport [137]. The mechan-
isms involved, either direct or indirect, remain to be
determined, but may involve the formation of axonal
aggregates. These neurofilament aggregates have been
proposed to impair axonal transport. Consistent with this
hypothesis, overexpression of neurofilament subunits in
transgenic mice is sufficient to inhibit transport, resulting in
degeneration of motor neurons [138,139].
14. Axonal transport defects in other neurodegenerative
diseases
14.1. Polyglutamine diseases
Polyglutamine diseases are a family of adult onset
neurodegenerative diseases caused by the expansion of a
glutamine-encoding CAG tract within the coding regions of
various ubiquitously expressed genes (reviewed in [140]).
Huntington's disease is caused by a CAG expansion in a protein
of unknown function, huntingtin, and results in progressive
motor deficits, as well as cognitive and personality changes.
CAG tract expansion in the androgen receptor gene is
responsible for Spinal and Bulbar Muscular Atrophy (SBMA)
a disease characterized by slowly progressive weakness in
proximal limbs and bulbar muscles [141,142].
Recent data from several models of polyglutamine disease
have suggested that abnormalities in axonal transport contribute
to pathology. Swollen axons containing accumulated vesicular
proteins are seen in several animal models of Huntington's
disease, as well as in patient tissue [143–148]. A neuronal
model of SBMA similarly showed aggregates containing
mutant androgen receptor, mitochondria, and anterograde
motor proteins blocking dystrophic neurites [149], suggesting
that deficits in anterograde transport contribute to pathology.
Both anterograde and retrograde transport were impaired in
squid axoplasm models of Huntington's disease and SBMA[150]; however, there was no evidence of aggregation or altered
distribution of motor proteins. Thus, physical blockade of the
axon may not be necessary to cause transport deficits.
Drosophila models of Huntington's disease also indicate
abnormalities in both anterograde and retrograde transport
[151]. Recent data suggest a mechanism by which expanded
huntingtin may disrupt axonal transport. Huntingtin interacts
with the p150Glued subunit of dynactin indirectly, via the
huntingtin-associated protein HAP1 [152]. Expanded glutamine
repeats in huntingtin have been proposed to disrupt the integrity
of the dynein/dynactin complex, thus reducing the efficiency of
BDNF transport and contributing to neuronal death [153].
14.2. Alzheimer's disease
Axonal aggregates of vesicles, organelles, and kinesin have
been observed in Alzheimer's disease (AD) patients with either
the Swedish or London mutations in amyloid precursor protein
(APP) [154]. Overexpression of APP causes similar axonal
blockages in both fly and mouse models of disease [155]. These
swellings occur well before the onset of symptoms or amyloid
deposition, suggesting a causal role [154]. The axonal transport
of APP is dependent on kinesin [156], and genetic reduction of
kinesin light chain 1 (KLC1) expression enhances axonal
accumulations [155]. Further, deficiencies in kinesin-based
transport have been observed in neurons with a mutation in
presenilin-1 [157]. It has been proposed that prolonging
transport of APP may increase its exposure to γ-secretase,
thus enhancing pathogenic proteolysis [154].
15. Unraveling mechanisms of neurodegeneration
Mutations in the motors that drive axonal transport are
clearly sufficient to cause motor neuron degeneration. Patients
with missense mutations in either dynactin or kinesin develop
neuropathies; observations in mouse models support these
findings. Further, defects in axonal transport contribute to the
pathology induced by mutations in other genes, including
SOD1. However, to date, defects in axonal transport have not
been shown to cause ALS. For example, the clinical
presentation of patients with the G59S mutation in the
DCTN1 gene is considerably less severe than that observed in
patients with classic ALS [118].
Therefore, it remains unclear whether defects in axonal
transport are a causative or a contributory factor in ALS. The
extended axons of motor neurons make these cells uniquely
vulnerable to defects in active transport, so it is reasonable to
propose that even when other defects, such as aggregation of
mutant SOD1, are a proximal cause of disease, a secondary
inhibition of axonal transport may play a critical role in the
downstream pathogenic mechanisms. It may be that multiple
insults to the neuron, including both genetic and environmental
factors, may cumulatively lead to impaired axonal transport.
What is striking is how subtle this impairment may need to be to
start a cascade of degeneration in the cell, as even very mild
impairments in transport can lead to the slowly progressive
degeneration of motor neurons.
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answered. What are the downstream effects of transport deficits
that lead to neurodegeneration and cell death? In some cases, it
may be a failure to supply new material to the distal axon, so
that synapses degrade over time. Defects in anterograde motors
can lead to distal neuropathies, consistent with this hypothesis.
In other cases, neuronal degeneration may result from the
accumulation of toxic substances at the distal end of the axon.
The retrograde motor dynein has a critical role in “taking out the
trash”; inhibition of retrograde transport may therefore lead to a
failure to degrade defective or damaged proteins. Defects in the
dynein/dynactin pathway result in motor neuron degeneration
with evidence of protein aggregation, consistent with this
hypothesis.
Both of these possibilities put the focus on distal events, so
that the degeneration of the motor neuron may best be viewed as
an axonopathy [158]. Alternatively, the key defect in many
cases may lie in inhibition of essential signaling pathways.
Cytoplasmic dynein participates in neurotrophic signaling,
driving the transport of Trk receptors, and this transport may
be critical to obtaining the full range of cellular responses. Thus,
inhibition of transport would lead to a block in communication
between target tissue and the motor neuron cell nucleus. Under
these conditions, loss of signaling may lead to the activation of
programmed cell death pathways.
In a related mechanism, the role of axonal transport in injury
response signaling [46,159] suggests that active transport may
be involved in maintaining plasticity. While motor neurons do
not regenerate, degradation of existing neuromuscular junctions
leads to sprouting, which in turn can lead to the reestablishment
of active junctions. Impairment of the cellular pathway for
injury signaling and damage response may lead to an impaired
ability of the motor neuron to recover from cellular stress.
Further complicating our understanding of the underlying
mechanisms of motor neuron cell death is the strong likelihood
that multiple interacting pathways are involved. For example,
impaired axonal transport may lead to the mislocalization of
mitochondria along the axon. This mislocalization may in turn
lead to mitochondrial mysfunction. This in turn may alter calcium
homeostasis or activate the apoptotic pathway. Alternatively, a
subtle impairment in neurofilament transport may lead to
increased aggregation, a common marker for ALS, and this
aggregation in turn can cause further damage either directly
through the steric inhibition of organelle transport along the axon,
or indirectly through cellular stress pathways. Finally, motor
neurons that are stressed for any of the above reasons may then be
more susceptible to excitotoxicity, leading to enhanced cell death.
While the cellular mechanisms that underlie the pathogenesis
of ALS are still far from clear, what is clear is the rapid progress
that has been made in recent years in understanding the role of
molecular motor proteins and the cytoskeleton in motor
neurons. A powerful combination of genetic, cellular, and
biochemical approaches have revealed new and often unex-
pected insights, and the further development of our understand-
ing of axonal transport in both normal and degenerating neurons
will hopefully continue to lead to the development of improved
therapies for those suffering from ALS.References
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